



**Almirall Nordic**

Att: Peter Berg Nielsen

March 27, 2026

**Follow up email from Almirall Nordic to LEO Pharma Nordic, Tuesday 24<sup>th</sup> of March.**

Dear Peter,

Thank you for your email and your concerns regarding LEO Pharma's presentation of price information relating to Adtralza (tralokinumab) in comparison with other biologic treatments for atopic dermatitis.

LEO Pharma takes compliance with the Ethical Rules for the Pharmaceutical Industry (LER) very seriously. Against this background, we have carefully reviewed the material in question and the points raised in your correspondence.

The price information presented is based exclusively on publicly available AUP list prices and dosing regimens as set out in the respective SmPCs. This approach is consistent with established Swedish practice for presenting illustrative price information where confidential rebate agreements apply and where net prices are not publicly available or verifiable. The calculations and assumptions used are transparent and can be independently confirmed.

The material also clearly states that national rebate and payback agreements apply to all relevant products. This information is included to ensure that recipients are aware that list prices do not reflect confidential arrangements between companies and regions.

Importantly, the price information is presented solely as an illustrative comparison based on publicly available AUP list prices and dosing in accordance with the respective SmPCs. The comparison is not intended to reflect actual net prices, tender results, or the effective cost to individual regions, as such information is subject to confidential arrangements, is not publicly verifiable, and may vary between regions and over time. Accordingly, the material does not claim, either expressly or by implication, that the list-price comparison represents real purchasing costs or demonstrates overall cost-effectiveness in clinical practice.

Against this background, LEO Pharma considers that the material, when assessed as a whole and in its intended context, is consistent with the requirements of objectivity, accuracy and non-misleading communication under the LER rules. The presentation of list-price-based calculations, together with clear information on their limitations, is in line with accepted standards for pharmaceutical information in Sweden.

LEO Pharma will continue to ensure that any price-related information is presented in accordance with applicable ethical rules, including clear communication of the basis and limitations of such information.

Kind regards,

**Anja Verhaug**

General Manager

LEO Pharma Nordic

Main +47 91 18 48 07

Mail [aveno@leo-pharma.com](mailto:aveno@leo-pharma.com)